BioPharmaBoardroom · Jul 2026
Latest industry coverage highlighting Synthio’s clinical-grade voice AI platform, named customers, and the company’s positioning around compliant pharma engagement.
Agentic AI platform for Pharma GTM teams
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Synthio Labs is a YC-backed, San Francisco–based 2024 startup building a clinical-grade agentic/voice AI platform for life sciences. Its product suite is aimed at pharma GTM and customer engagement workflows across HCP engagement, patient support, field enablement, and market research.
Primary product
Clinical-grade Voice AI operating system for life sciences
Founded
2024
Headquarters
San Francisco Bay Area, California, United States
Team size
20-30
Work style
Flexible
Industry
Software Development
Sub-industry
Life sciences / pharma AI and voice AI
Offices
0 jobs at SynthioLabs
Check back later for new openings
Business model
Stage
Seed
Total raised
$5M
Latest round
Seed · Nov 2025
Latest amount
$5M
Nov 2025 · Elevation Capital
Leadership
Co-Founder and CEO
Co-Founder and CTO
Co-Founder and Chief Product Officer
Investors
Ownership-heavy, AI-native, and fast-moving; the careers page emphasizes agency, curiosity, AI with purpose, and using AI as a daily teammate while staying focused on safety, accuracy, and empathy.
Work style
Flexible
Compensation
Public job posts mention competitive compensation and equity; one YC listing shows a $15K-$25K pay range for the India remote software engineer role.
Benefits
Pricing
Enterprise sales / book-a-demo
Differentiators
Technology
Customers
Estimated revenue
Third-party estimates conflict: roughly $0.77M ARR (GetLatka) to about $7.0M ARR (StartupHub).
Estimated monthly visits
22.8K
Traffic estimate as of Jul 2026
BioPharmaBoardroom · Jul 2026
Latest industry coverage highlighting Synthio’s clinical-grade voice AI platform, named customers, and the company’s positioning around compliant pharma engagement.
BusinessWire · Nov 2025
Official seed-round announcement: $5M led by Elevation Capital with participation from 1984 Ventures, Peak XV Partners, Y Combinator, and strategic angels; details the product suite and go-to-market expansion plans.
The Economic Times · Nov 2025
Covers the seed round, the company’s pharma engagement use case, and plans to expand in the U.S. and Europe.
YourStory · Nov 2025
Reports the seed round and emphasizes the company’s life-sciences engagement product, team distribution across India and the U.S., and planned expansion.
Inc42 · Nov 2025
Profiles the startup, its founding team, and its Jarvis/Ather/Simulation Studio product suite; confirms the seed funding and enterprise life-sciences focus.